---
title: "Beta Bionics, Inc. (BBNX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BBNX.US.md"
symbol: "BBNX.US"
name: "Beta Bionics, Inc."
industry: "Health Care Equipment"
datetime: "2026-03-03T12:41:37.854Z"
locales:
  - [en](https://longbridge.com/en/quote/BBNX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BBNX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BBNX.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BBNX.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BBNX.US.md)


# Beta Bionics, Inc. (BBNX.US)

## Company Overview

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.betabionics.com](https://www.betabionics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:16.000Z

**Overall: C (0.41)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 64 / 186 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 53.94% |  |
| Net Profit YoY | -33.68% |  |
| P/B Ratio | 1.93 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 555664467.92 |  |
| Revenue | 100251000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -346.51% | E |
| Profit Margin | -73.02% | E |
| Gross Margin | 55.40% | B |
| Revenue YoY | 53.94% | A |
| Net Profit YoY | -33.68% | D |
| Total Assets YoY | 119.68% | A |
| Net Assets YoY | 278.37% | A |
| Cash Flow Margin | -136.95% | D |
| OCF YoY | 53.94% | A |
| Turnover | 0.42 | C |
| Gearing Ratio | 12.51% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beta Bionics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "53.94%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-33.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.93",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "555664467.92",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "100251000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-346.51%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-73.02%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "55.40%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "53.94%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-33.68%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "119.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "278.37%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-136.95%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "53.94%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.51%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.59 | 133/186 | - | - | - |
| PB | 1.93 | 52/186 | 4.06 | 2.66 | 2.07 |
| PS (TTM) | 5.54 | 92/186 | 13.77 | 10.74 | 7.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Inspire Medical (INSP.US) | A | B | A | A | B | A |
| 02 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 03 | Abbott Laboratories (ABT.US) | B | C | C | B | C | B |
| 04 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 05 | Stryker (SYK.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-18T05:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 67% |
| Overweight | 1 | 8% |
| Hold | 3 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.52 |
| Highest Target | 32.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BBNX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BBNX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BBNX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BBNX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**